Lee Jae Min, Park Yehyun, Ahn Dong Won, Lee Jun Kyu, Lee Kwang Hyuck
Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea.
Department of Internal Medicine, Ewha Womans University Seoul Hospital, Seoul, Korea.
Clin Endosc. 2025 May;58(3):370-376. doi: 10.5946/ce.2024.026. Epub 2025 Jan 14.
Remimazolam is a novel benzodiazepine with unique pharmacokinetic and pharmacodynamic properties, making it an ideal candidate for sedation during endoscopic procedures. Distinguished by its rapid onset and short duration of action, remimazolam offers a safer and more efficient alternative to traditional sedatives, such as midazolam and propofol, with fewer side effects, such as hypotension, bradycardia, and respiratory depression. This article reviews the characteristics of remimazolam and its practical advantages, including ease of use, quick recovery time, and minimal residual sedation, emphasizing its potential to improve patient safety and procedural efficiency in clinical endoscopy settings.
瑞马唑仑是一种新型苯二氮䓬类药物,具有独特的药代动力学和药效学特性,使其成为内镜手术镇静的理想选择。瑞马唑仑以其起效迅速和作用时间短为特点,与咪达唑仑和丙泊酚等传统镇静剂相比,提供了一种更安全、更有效的替代方案,副作用更少,如低血压、心动过缓和呼吸抑制。本文综述了瑞马唑仑的特点及其实际优势,包括使用方便、恢复时间快和残余镇静作用极小,强调了其在临床内镜检查中提高患者安全性和手术效率的潜力。